Expression and clinical significance of P62 and P21 in bile duct and gallbladder carcinomas

Abstract

Objective To investigate the expression of P62, a oncogene C-mycproduct, and P21, a oncogene H-ras product, in bile duct and gallbladder diseases and explore its clinical significance. Methods The expression of P62 and P21 was detected with immunohistochemistry in 30 cases of cholangiocarcinoma, 28 cases of gallbladder carcinoma and 30 cases of benign bile duct and gallbladder diseases. Results The rates of over-expression of P62 and P21 in the 30 cases of cholangiocarcinoma were 66.7% and 63.3%， respectively， but 10% and 0% in cases of benign bile duct diseases. There was a significant difference between these 2 groups of patients (P<0.05). The rates of over-expression of P62 and P21 in 28 cases of gallbladder carcinoma were 42.8% and 57.1%, respectively but 10% and 5% in cases of benign gallbladder diseases. There was also a significant difference between these 2 groups of patients (P<0.05). In the cases of bile duct and gallbladder carcinomas, the degree of the over-expression of P62 and P21 was consistent with pathohistological features of the tumors and closely correlated to the size of the primary lesion and the position of lymph metastasis. Conclusions P62 And P21 are over-expressed in bile duct and gallbladder carcinomas. They are related to the pathological type, malignancy, focal size and lymph metastasis of the tumors. Therefore, they are of certain reference value in diagnosis, differential diagnosis and judgement of prognosis of the tumors.